Mira Pharmaceuticals, Common Stock Analysis
| MIRA Stock | 1.15 0.10 8.00% |
MIRA Pharmaceuticals, Common is undervalued with Real Value of 4.98 and Target Price of 16.5. The main objective of MIRA Pharmaceuticals, stock analysis is to determine its intrinsic value, which is an estimate of what MIRA Pharmaceuticals, Common is worth, separate from its market price. There are two main types of MIRA Pharmaceuticals,'s stock analysis: fundamental analysis and technical analysis.
The MIRA Pharmaceuticals, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and MIRA Pharmaceuticals,'s ongoing operational relationships across important fundamental and technical indicators.
MIRA |
MIRA Stock Analysis Notes
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.55. MIRA Pharmaceuticals, had not issued any dividends in recent years. To find out more about MIRA Pharmaceuticals, Common contact Erez Aminov at 786-432-9792 or learn more at https://mirapharmaceuticals.com.MIRA Pharmaceuticals, Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. MIRA Pharmaceuticals,'s investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding MIRA Pharmaceuticals, Common or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| MIRA Pharmaceuticals, generated a negative expected return over the last 90 days | |
| MIRA Pharmaceuticals, has high historical volatility and very poor performance | |
| MIRA Pharmaceuticals, may become a speculative penny stock | |
| MIRA Pharmaceuticals, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.98 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| MIRA Pharmaceuticals, generates negative cash flow from operations | |
| MIRA Pharmaceuticals, has a poor financial position based on the latest SEC disclosures | |
| About 27.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: MIRA Pharmaceuticals Validates Ketamir-2s Safety Profile with No Adverse Findings, Paving the Way for IND Submission by Year-End |
MIRA Pharmaceuticals, Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MIRA Pharmaceuticals, previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of December 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
MIRA Largest EPS Surprises
Earnings surprises can significantly impact MIRA Pharmaceuticals,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-13 | 2024-03-31 | -0.1 | -0.12 | -0.02 | 20 | ||
2024-02-28 | 2023-12-31 | -0.23 | -0.3915 | -0.1615 | 70 | ||
2023-11-13 | 2023-09-30 | -0.08 | -0.26 | -0.18 | 225 |
MIRA Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.7 M.MIRA Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.43) | (2.55) | |
| Return On Capital Employed | (1.95) | (1.85) | |
| Return On Assets | (2.43) | (2.55) | |
| Return On Equity | (2.74) | (2.60) |
Management Efficiency
MIRA Pharmaceuticals, has return on total asset (ROA) of (1.7753) % which means that it has lost $1.7753 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4859) %, meaning that it created substantial loss on money invested by shareholders. MIRA Pharmaceuticals,'s management efficiency ratios could be used to measure how well MIRA Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of December 12, 2024, Return On Tangible Assets is expected to decline to -2.55. The current year's Return On Capital Employed is expected to grow to -1.85. The current year's Total Current Assets is expected to grow to about 5.1 M, whereas Total Assets are forecasted to decline to about 2.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.24 | 0.25 | |
| Tangible Book Value Per Share | 0.24 | 0.25 | |
| Enterprise Value Over EBITDA | (12.11) | (12.71) | |
| Price Book Value Ratio | 4.46 | 4.68 | |
| Enterprise Value Multiple | (12.11) | (12.71) | |
| Price Fair Value | 4.46 | 4.68 | |
| Enterprise Value | 85.3 M | 75.1 M |
The strategic initiatives led by MIRA Pharmaceuticals,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Assets (1.78) | Return On Equity (7.49) |
Technical Drivers
As of the 12th of December 2024, MIRA Pharmaceuticals, secures the risk adjusted performance of 0.0148, and Mean Deviation of 4.83. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of MIRA Pharmaceuticals,, as well as the relationship between them.MIRA Pharmaceuticals, Price Movement Analysis
The output start index for this execution was fourty-one with a total number of output elements of twenty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. MIRA Pharmaceuticals, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for MIRA Pharmaceuticals,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
MIRA Pharmaceuticals, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MIRA Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on MIRA Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MIRA Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MIRA Pharmaceuticals, Predictive Daily Indicators
MIRA Pharmaceuticals, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MIRA Pharmaceuticals, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 224891.0 | |||
| Daily Balance Of Power | (0.32) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 1.13 | |||
| Day Typical Price | 1.13 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.10) |
MIRA Pharmaceuticals, Forecast Models
MIRA Pharmaceuticals,'s time-series forecasting models are one of many MIRA Pharmaceuticals,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MIRA Pharmaceuticals,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About MIRA Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how MIRA Pharmaceuticals, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MIRA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MIRA Pharmaceuticals,. By using and applying MIRA Stock analysis, traders can create a robust methodology for identifying MIRA entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current MIRA Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MIRA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MIRA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 16.5 | Strong Buy | 2 | Odds |
Most MIRA analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MIRA stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of MIRA Pharmaceuticals,, talking to its executives and customers, or listening to MIRA conference calls.
MIRA Stock Analysis Indicators
MIRA Pharmaceuticals, Common stock analysis indicators help investors evaluate how MIRA Pharmaceuticals, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MIRA Pharmaceuticals, shares will generate the highest return on investment. By understating and applying MIRA Pharmaceuticals, stock analysis, traders can identify MIRA Pharmaceuticals, position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 350.98 | |
| Common Stock Shares Outstanding | 18.6 M | |
| Total Stockholder Equity | 4.4 M | |
| Property Plant And Equipment Net | 5061.00 | |
| Cash And Short Term Investments | 4.6 M | |
| Cash | 4.6 M | |
| Accounts Payable | 538.6 K | |
| Net Debt | -4.6 M | |
| 50 Day M A | 1.3631 | |
| Total Current Liabilities | 558.1 K | |
| Other Operating Expenses | 8.5 M | |
| Non Current Assets Total | 74.2 K | |
| Non Currrent Assets Other | 69.2 K | |
| Stock Based Compensation | 2.6 M |
Complementary Tools for MIRA Stock analysis
When running MIRA Pharmaceuticals,'s price analysis, check to measure MIRA Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MIRA Pharmaceuticals, is operating at the current time. Most of MIRA Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of MIRA Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MIRA Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of MIRA Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |